CL2011000032A1 - Compuestos derivados macrocíclicos de indol[2,1-a]benzacepina sustituidos; composición farmacéutica que los comprende; y su uso para inhibir la replicación del virus de la hepatitis e (hcv). - Google Patents

Compuestos derivados macrocíclicos de indol[2,1-a]benzacepina sustituidos; composición farmacéutica que los comprende; y su uso para inhibir la replicación del virus de la hepatitis e (hcv).

Info

Publication number
CL2011000032A1
CL2011000032A1 CL2011000032A CL2011000032A CL2011000032A1 CL 2011000032 A1 CL2011000032 A1 CL 2011000032A1 CL 2011000032 A CL2011000032 A CL 2011000032A CL 2011000032 A CL2011000032 A CL 2011000032A CL 2011000032 A1 CL2011000032 A1 CL 2011000032A1
Authority
CL
Chile
Prior art keywords
replication
hcv
inhibit
benzacepin
hepatitis
Prior art date
Application number
CL2011000032A
Other languages
English (en)
Spanish (es)
Inventor
Sandrine Marie Hélène Vendeville
Pierre Jean-Marie Bernard Raboisson
Tse-I Lin
Abdellah Tahri
Katie Ingrid Eduard Amssoms
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of CL2011000032A1 publication Critical patent/CL2011000032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2011000032A 2008-07-08 2011-01-07 Compuestos derivados macrocíclicos de indol[2,1-a]benzacepina sustituidos; composición farmacéutica que los comprende; y su uso para inhibir la replicación del virus de la hepatitis e (hcv). CL2011000032A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08161743 2008-08-04

Publications (1)

Publication Number Publication Date
CL2011000032A1 true CL2011000032A1 (es) 2011-07-15

Family

ID=40972916

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000032A CL2011000032A1 (es) 2008-07-08 2011-01-07 Compuestos derivados macrocíclicos de indol[2,1-a]benzacepina sustituidos; composición farmacéutica que los comprende; y su uso para inhibir la replicación del virus de la hepatitis e (hcv).

Country Status (31)

Country Link
US (2) US8921355B2 (https=)
EP (1) EP2310396B1 (https=)
JP (2) JP5426671B2 (https=)
KR (1) KR101640374B1 (https=)
CN (1) CN102089314B (https=)
AP (1) AP2743A (https=)
AR (1) AR072726A1 (https=)
AU (1) AU2009267389B8 (https=)
BR (1) BRPI0915887B8 (https=)
CA (1) CA2729307C (https=)
CL (1) CL2011000032A1 (https=)
CO (1) CO6351793A2 (https=)
CR (1) CR20110076A (https=)
DK (1) DK2310396T3 (https=)
EA (1) EA019008B1 (https=)
EC (1) ECSP11010750A (https=)
ES (1) ES2651038T3 (https=)
HN (1) HN2011000072A (https=)
HR (1) HRP20171892T1 (https=)
HU (1) HUE035244T2 (https=)
IL (1) IL210086A (https=)
LT (1) LT2310396T (https=)
MX (1) MX2011000276A (https=)
NI (1) NI201100010A (https=)
NO (1) NO2310396T3 (https=)
NZ (2) NZ590073A (https=)
SI (1) SI2310396T1 (https=)
SV (1) SV2011003796A (https=)
TW (1) TWI454476B (https=)
UY (1) UY31973A (https=)
WO (1) WO2010003658A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2389994T3 (es) 2007-12-24 2012-11-05 Janssen R&D Ireland Indoles macrocíclicos como inhibidores del virus de la hepatitis C
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20130028865A1 (en) * 2010-04-13 2013-01-31 Medivir Ab Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
CA2801517C (en) * 2010-06-24 2017-12-12 Janssen R&D Ireland Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7h-indolo-[2,1-.alpha.]-[2]-benzazepine-10-carboxylic acid
HUE035751T2 (hu) 2011-09-02 2018-08-28 Novartis Ag Gyulladásgátló szubsztituált ciklobuténdion vegyület kolinsó
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
US20150209366A1 (en) 2012-08-31 2015-07-30 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
WO2019133574A2 (en) * 2017-12-26 2019-07-04 Southern Research Institute Benzoannulene derivatives as antiviral agents
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
CN116425782A (zh) * 2023-03-22 2023-07-14 烟台盛凯伦化学科技有限公司 一种5-乙酰基-2-氟苯硼酸频哪醇酯的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
CA2367017C (en) 1999-03-19 2009-05-26 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
JP4778665B2 (ja) 2000-08-30 2011-09-21 パナソニック株式会社 プラズマディスプレイ表示装置の製造方法
PL1713822T3 (pl) 2004-01-30 2010-08-31 Medivir Ab Inhibitory proteazy serynowej HCV NS-3
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
AU2006286441A1 (en) 2005-09-02 2007-03-08 Janssen R&D Ireland Benzodiazepines as HCV inhibitors
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2008043704A1 (en) 2006-10-10 2008-04-17 Medivir Ab Hcv nucleoside inhibitor
CA2672250C (en) 2006-12-20 2013-04-30 Ian Stansfield Antiviral indoles
JP2010533699A (ja) * 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎感染症の治療のための大環状インドール誘導体
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
AR073603A1 (es) 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
PL2401272T3 (pl) 2009-02-27 2017-06-30 Janssen Pharmaceuticals, Inc. Amorficzna sól makrocyklicznego inhibitora HCV
US20130028865A1 (en) 2010-04-13 2013-01-31 Medivir Ab Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
CA2801517C (en) 2010-06-24 2017-12-12 Janssen R&D Ireland Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7h-indolo-[2,1-.alpha.]-[2]-benzazepine-10-carboxylic acid
US20150209366A1 (en) 2012-08-31 2015-07-30 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir

Also Published As

Publication number Publication date
NO2310396T3 (https=) 2018-02-03
SI2310396T1 (en) 2018-01-31
HUE035244T2 (hu) 2018-05-02
AU2009267389A8 (en) 2013-07-04
BRPI0915887B8 (pt) 2021-05-25
HN2011000072A (es) 2013-09-01
IL210086A0 (en) 2011-02-28
WO2010003658A1 (en) 2010-01-14
UY31973A (es) 2010-01-29
JP2011527299A (ja) 2011-10-27
MX2011000276A (es) 2011-03-02
JP5426671B2 (ja) 2014-02-26
JP5808370B2 (ja) 2015-11-10
CN102089314B (zh) 2014-07-23
IL210086A (en) 2014-05-28
US20110105473A1 (en) 2011-05-05
KR101640374B1 (ko) 2016-07-18
CR20110076A (es) 2011-11-10
TWI454476B (zh) 2014-10-01
BRPI0915887B1 (pt) 2020-02-18
AR072726A1 (es) 2010-09-15
JP2014028818A (ja) 2014-02-13
NZ590073A (en) 2012-11-30
EP2310396A1 (en) 2011-04-20
LT2310396T (lt) 2017-12-27
AU2009267389B2 (en) 2013-05-30
HK1155734A1 (en) 2012-05-25
EA019008B1 (ru) 2013-12-30
AP2743A (en) 2013-09-30
ECSP11010750A (es) 2011-08-31
US9427440B2 (en) 2016-08-30
HRP20171892T1 (hr) 2018-01-12
EP2310396B1 (en) 2017-09-06
US8921355B2 (en) 2014-12-30
AP2010005521A0 (en) 2010-12-31
EA201170153A1 (ru) 2011-08-30
TW201014865A (en) 2010-04-16
NI201100010A (es) 2011-09-07
DK2310396T3 (en) 2017-12-11
KR20110040889A (ko) 2011-04-20
NZ603343A (en) 2013-08-30
AU2009267389A1 (en) 2010-01-14
AU2009267389B8 (en) 2013-07-04
CO6351793A2 (es) 2011-12-20
CN102089314A (zh) 2011-06-08
US20140107101A1 (en) 2014-04-17
CA2729307A1 (en) 2010-01-14
SV2011003796A (es) 2011-04-08
ES2651038T3 (es) 2018-01-23
BRPI0915887A2 (pt) 2015-11-03
CA2729307C (en) 2017-08-29

Similar Documents

Publication Publication Date Title
CL2011000032A1 (es) Compuestos derivados macrocíclicos de indol[2,1-a]benzacepina sustituidos; composición farmacéutica que los comprende; y su uso para inhibir la replicación del virus de la hepatitis e (hcv).
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
HN2012001162A (es) Triazolopiridinas
ECSP12011867A (es) Derivados bencimidazol-imidazol
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CL2011001332A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica que los comprende; y su uso para el tratamiento del virus de la hepatitis c (vhc).
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
BRPI0922366B8 (pt) composto, composição farmacêutica e uso de um composto
CL2019001993A1 (es) Inhibidores selectivos de jak1.
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
UY32759A (es) Inhibidores del virus de la hepatitis c
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
ECSP077335A (es) Inhibidores de la interaccion entre mdm2 y p53
GT200600341A (es) Inhibidores macrociclicos del virus de la hepatitis c
PE20160605A1 (es) Formulaciones de inhibidores de la syk
GT201300254A (es) Triazolopiridinas
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
NI200700102A (es) Derivados de indol tetraciclicos como agentes antiviricos
ECSP11010878A (es) Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv.
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.